Literature DB >> 7903927

Use of anxiolytics in children.

J G Siméon1.   

Abstract

Anxiety disorders are among the most frequent of childhood psychiatric disorders. These disorders can persist from childhood and adolescence into adulthood, resulting in impaired functioning at home, school or work. Some anxiety disorders like generalized or separation anxiety are acute requiring urgent, short-term treatment. Others like fears or inhibitions are chronic resulting in longterm handicaps. Other psychiatric disorders may be concurrent with, or misdiagnosed as, anxiety disorder. Anxiety can be associated with mood or behavioral disorders. When anxiety is symptomatic of another disorder, the primary disorder should be treated first. The pharmacology of childhood anxiety has been hindered by the lack of reliable quantitative evaluations, and the changes in the manifestations of anxiety. Various types of drugs have been used to treat anxiety and related disorders. The use of different drugs is reviewed. The results of a controlled clinical trial with alprazolam and two trials with buspirone in the treatment of child and adolescent anxiety are presented. While these results are promising, further clinical trials are a priority.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7903927

Source DB:  PubMed          Journal:  Encephale        ISSN: 0013-7006            Impact factor:   1.291


  3 in total

Review 1.  Buspirone in Children and Adolescents with Anxiety: A Review and Bayesian Analysis of Abandoned Randomized Controlled Trials.

Authors:  Jeffrey R Strawn; Jeffrey A Mills; Gary J Cornwall; Sarah A Mossman; Sara T Varney; Brooks R Keeshin; Paul E Croarkin
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-08-28       Impact factor: 2.576

Review 2.  Pharmacological treatment of psychiatric disorders in children and adolescents: focus on guidelines for the primary care practitioner.

Authors:  N J Carrey; D M Wiggins; R P Milin
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 3.  School refusal: epidemiology and management.

Authors:  D Heyne; N J King; B J Tonge; H Cooper
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.